What five retatrutide trials showed about health

What the strongest retatrutide findings leave open

Eli Lilly designed retatrutide to change hunger, insulin release, and calorie burning together. The drug copies GLP-1, a hunger hormone, and other hormones that help manage sugar and fat.

Phase 2, the middle testing stage, found average weight loss reaching 24.2% over 48 weeks. These were the largest losses then reported in a drug trial, though your safety over years remained uncertain.

The TRIUMPH Phase 3 trials use larger groups before a possible decision on approval. Initial Phase 3 findings appeared in 2026, but retatrutide remained unapproved worldwide as of 2026.

Retatrutide research below covers Phase 1b, early tests, followed by Phase 2 middle tests and Phase 3 larger tests. The people involved, time spent in treatment, and problems doctors found all matter to your understanding.

What the hormone actions do, and what cell tests cannot prove

Retatrutide also goes by the study name LY3437943, which refers to the same drug. Scientists wanted retatrutide to curb hunger and lower weight while improving sugar control.

Powerful microscopes showed retatrutide touching cells sensitive to hormones ^[3]. Scientists compared the drug's effect with the effects of hormones managing hunger, insulin release, and calorie burning.

The tests measured how strongly the drug acted on cells in a dish. Your weight loss and comfort cannot be predicted from the reactions of cells.

Retatrutide's GLP-1 action reduces hunger while food stays longer in your stomach. GIP prompts insulin release when blood sugar increases, while glucagon helps use calories and break down liver fat.

Reviews describe larger weight losses than medicines with only one of these actions ^[8][11]. That may mean fewer calories eaten and more used, but it isn't a forecast for your own weight.

A 2024 review suggested losses might approach those achieved with weight-loss surgery ^[11]. The authors drew on earlier findings; they didn't prove retatrutide could take the place of surgery.

What Phase 1b, early tests, found in weight and blood checks

Over 12 weeks, the largest amount produced greater loss than the treatment containing no retatrutide. Placebo contained no retatrutide, letting doctors compare changes with and without the drug.

The early Phase 1b trial followed 72 adults with type 2 diabetes for 12 weeks ^[4]. Weekly amounts ran from 0.5 milligrams to 12 milligrams, with doctors checking sugar, weight, and unwanted effects.

The study's 90% confidence check described how sure researchers were about the estimated average weight loss. That percentage wasn't a count of people who lost weight or a prediction for you.

Blood checks found roughly half the drug still present after 6 days, which supported testing weekly injections. Daily sugar improved at 3 milligrams, while 63% had unwanted effects, mostly stomach and gut trouble ^[4].

Nobody in the study had dangerously low sugar, though the small group couldn't settle every risk. Phase 1b helped researchers plan gradual increases for later trials, without choosing an approved schedule or amount for your care.

What Phase 2, middle tests, found in obesity over 48-week treatment

At 12 milligrams, average weight loss reached 24.2%; placebo, a treatment without retatrutide, produced 2.1% loss ^[1]. Both describe the weight lost from the start, rather than extra loss beyond placebo.

The middle study stage, Phase 2, followed 338 adults without diabetes for 48 weeks. A height-and-weight score of 30 or more marked obesity; scores from 27 to 30 qualified with another weight-related illness.

Weekly groups received 1, 4, 8, or 12 milligrams after gradual increases under medical care ^[1]. At 48 weeks, waists had also shrunk with 12 milligrams, though a smaller waist doesn't settle your safety.

Nausea, a sick stomach, affected up to 45% at 12 milligrams. Unwanted effects led 18% to stop at 12 milligrams, and larger amounts caused more gut trouble.

The biggest pulse rises came near week 24 and then partly eased. That easing doesn't answer whether years of treatment would be safe for your heart.

A 2025 commentary described losses reaching 24% as a major advance for weight medicines ^[6]. A 2024 review compared losses with weight-loss surgery ^[11], though no study directly compared retatrutide against surgery.

What Phase 2, middle tests, found in type 2 diabetes over 36-week treatment

At 24 weeks, sugar control was better with 12 milligrams than with placebo, a treatment without retatrutide ^[2]. By 36 weeks, average weight loss was 16.94% with 12 milligrams and 3.00% with placebo.

The Phase 2 trial followed 281 adults whose type 2 diabetes remained poorly controlled on their usual medicines. Doctors gradually increased weekly amounts from 0.5 to 12 milligrams over 36 weeks ^[2].

Gut trouble affected 35% and was rated mild or moderate. Nobody died or had dangerously low sugar ^[2], though a limited trial cannot establish safety throughout your later years.

Weight still fell with 12 milligrams in people whose bodies didn't use insulin well. The loss was smaller than in the obesity trial, but different groups and study lengths make comparisons less certain.

What Phase 2a, a smaller middle test, found inside the liver

With 12 milligrams, liver fat fell 82.4% by 24 weeks; placebo produced a 0.3% rise ^[5]. Separately, 86% of the 12 milligram group reached normal levels, meaning their livers held less than 5% fat.

Phase 2a followed 98 overweight people who had at least 10% liver fat, without type 2 diabetes ^[5]. MRI, a scan using magnets to see inside the body, measured the fat.

By 48 weeks, scans showed further loss of liver fat with 12 milligrams. This drug family had not previously shown a larger drop, separate from how many people reached normal levels.

A review discussed possible wider benefits for the liver and heart ^[9]. Less fat is encouraging, but the scans can't promise that you would avoid illness later.

What Phase 3 larger tests showed, and what Phase 3 still leaves unknown

The 12 milligram group had better sugar control than placebo, which contained no retatrutide ^[12]. Average weight loss was 15.3% with 12 milligrams and 2.6% with placebo, each measured from starting weight.

Researchers followed 537 adults with type 2 diabetes for 40 weeks in the first Phase 3 report. Diet and exercise hadn't controlled their sugar adequately ^[12], so doctors tested whether retatrutide could help.

Most gut trouble was mild or moderate, though unwanted effects led 8.3% to stop retatrutide. Nobody had dangerously low sugar, but these findings can't establish safety over years for you.

Phase 3 uses larger groups before possible approval, and these early findings supported the Phase 2 benefits. Other TRIUMPH trials examine obesity, heart health, kidney disease, and a direct comparison with tirzepatide ^[8].

Retatrutide vs tirzepatide: what remains unknown about which works better

Retatrutide produced larger losses in separate studies, but your choice between drugs needs a more direct comparison. The direct TRIUMPH comparison had no published results by mid-2026 ^[8].

Retatrutide's Phase 2 middle test found average loss of 24.2% with 12 milligrams over 48 weeks. Tirzepatide's Phase 3 larger test found less loss, though the groups and their medical care could differ.

A 2025 review described retatrutide's greater losses while awaiting the direct comparison ^[8]. A 2026 review also described weight returning after related hunger medicines stopped ^[13].

Neither medicine has proved that weight lost reliably stays off once treatment ends. Tirzepatide is the drug's general name, so the comparison concerns the drug itself rather than a particular brand.